NovaBridge Biosciences (NBP) Change in Accured Expenses (2018 - 2025)

NovaBridge Biosciences (NBP) has 8 years of Change in Accured Expenses data on file, last reported at $10.7 million in Q4 2025.

• Change in Accured Expenses for Q4 2025 came in at $10.7 million, up 423.15% year-over-year; the trailing twelve-month figure through Dec 2025 was $39.2 million (changed N/A YoY), and the FY2025 annual result was $18.1 million, up 136.72% from the prior year.
• Change in Accured Expenses slipped to $10.7 million in Q4 2025 per NBP's latest filing, from $15.2 million in the prior quarter.
• Over five years, Change in Accured Expenses peaked at $99.3 billion in Q4 2022 and troughed at -$3.3 million in Q4 2024.
• A 5-year average of $18.6 billion and a median of $15.2 million in 2025 frame the typical range for Change in Accured Expenses.
• The sharpest annual moves came in 2021 and 2024: Change in Accured Expenses surged 321337.63% in 2021, then sank 100.01% in 2024.
• A 5-year view of Change in Accured Expenses shows it stood at $92.8 billion in 2021, then climbed by 7.05% to $99.3 billion in 2022, then tumbled by 49.99% to $49.7 billion in 2023, then plunged by 100.01% to -$3.3 million in 2024, then surged by 423.15% to $10.7 million in 2025.
• Business Quant data shows NBP's Change in Accured Expenses at $10.7 million in Q4 2025, $15.2 million in Q3 2025, and $6.5 million in Q2 2025.